DrugPatentWatch Database Preview
Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
» See Plans and Pricing
Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
Docket | Start Trial | Date Filed | 2017-06-26 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
Jury Demand | Defendant | Referred To | |
Parties | ACCORD HEALTHCARE INC.; ALKEM LABORATORIES LTD.; AMNEAL PHARMACEUTICALS LLC; AUROBINDO PHARMA U.S.A., INC.; AUROBINDO PHARMA USA LLC; BIOGEN INTERNATIONAL GMBH; BIOGEN MA INC.; CARIBE HOLDINGS (CAYMAN) CO. LTD.; CIPLA LIMITED; CIPLA USA INC.; DBA PURACAP CARIBE; GLENMARK PHARMACEUTICALS INC. USA; GLENMARK PHARMACEUTICALS LIMITED; GRAVITI PHARMACEUTICALS INC.; GRAVITI PHARMACEUTICALS PVT. LTD.; HETERO LABS LIMITED; HETERO LABS LIMITED UNIT-III; HETERO USA INC.; IMPAX LABORATORIES INC.; IMPAX LABORATORIES LLC; LUPIN ATLANTIS HOLDINGS SA; MACLEODS PHARMA USA, INC.; MACLEODS PHARMACEUTICALS LTD.; MSN LABORATORIES PRIVATE LTD.; MSN PHARMACEUTICALS INC.; PHARMATHEN S.A.; PRINSTON PHARMACEUTICAL INC.; PURACAP INTERNATIONAL LLC; S&B PHARMA, INC.; SANDOZ INC.; SAWAI PHARMACEUTICAL CO., LTD.; SAWAI USA INC.; SHILPA MEDICARE LIMITED; SLAYBACK PHARMA INDIA LLP; SLAYBACK PHARMA LLC; SUN PHARMA GLOBAL FZE; TEVA PHARMACEUTICALS USA INC.; TORRENT PHARMA INC.; TORRENT PHARMACEUTICALS LTD.; TWI PHARMACEUTICALS INC.; TWI PHARMACEUTICALS USA INC.; WINDLAS HEALTHCARE PVT. LTD.; ZYDUS PHARMACEUTICALS (USA) INC. | ||
Patents | 6,509,376; 6,926,907; 7,320,999; 8,399,514; 8,759,393 | ||
Attorneys | Aaron F. Barkoff; Adam Wyatt Poff; Alan Tenenbaum; Alejandro Menchaca; Alison M. Hill; Andrew Colin Mayo; Andrew E. Renison; Andy J. Miller; Anne Shea Gaza; Arthur G. Connolly , III; Benjamin J. Schladweiler; Bindu Ann George Palapura; Brian Sodikoff; Christopher B. Ferenc; Christopher M. Bruno; Christopher P. Galligan; David A. Bilson; David Ellis Moore; Dominick T. Gattuso; Don J. Mizerk; Dustin L. Taylor; Emily N. Winfield; Eric J. Fues; Erin M. Forbes; Erin R. Conway; Eve H. Ormerod; Frank D. Rodriguez; Frederick R. Ball; Gary Ji; George C. Lombardi; George J. Barry , III; Huiya Wu; Imron T. Aly; James B. Monroe; James E. Nealon; James P. Barabas; James S. Green , Jr.; Jeanette M. Roorda; Jeffer Ali; Jing Xia; John C. Phillips , Jr.; John E. Nappi; John R. McNair; Jonathan B. Turpin; Joseph E. Cwik; Joseph M. Reisman; Jovial Wong; Kelly E. Farnan; Kenton M. Walker; Kevin E. Warner; Laura P. Masurovsky; Li Feng; Loni L. Morrow; Mark Rubinshtein; Matthew M. Holub; Megan L. Meyers; Michael J. Gaertner; Michelle A. Herrera; Naomi L. Birbach; Neal C. Belgam; Patrick C. Gallagher; Paul W. Browning; Peter M. Kohlhepp; Philip D. Segrest; Philip Y. Braginsky; Pilar Gabrielle Kraman; Rachel P. Waldron; Rajendra A. Chiplunkar; Richard L. Renck; Samantha G. Wilson; Samuel Sherry; Sanya Sukduang; Sara E. Bussiere; Saukshmya Trichi; Scott B. Feder; Shailendra K. Maheshwari; Stamatios Stamoulis; Stephanie S. Riley; Stephen B. Brauerman; Steven J. Balick; Steven J. Moore; Thomas H. Ehrich; Thomas P. Krzeminski; Timothy F. Peterson; Timothy H. Kratz; Todd S. Werner; Vincent L. Capuano; William A. Rakoczy; William R. Zimmerman; Yun Wei | ||
Firms | Bayard, P.A.; Connolly Gallagher LLP; Duane Morris, LLP; Greenberg Traurig, the Nemours Building; Heyman Enerio Gattuso & Hirzel LLP; Phillips, Goldman, McLaughlin & Hall, P.A.; Smith, Katzenstein, & Jenkins LLP; Stamoulis & Weinblatt LLC; Young, Conaway, Stargatt & Taylor LLP | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Biogen International GmbH v. Amneal Pharmaceuticals LLC
Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-08-31 | 166 | Stipulation of Dismissal | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
2019-03-07 | 236 | Memorandum Opinion | infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the ' …393 patent"), and 8,399,514 ("the ' 514 patent") (collectively, "patents-in-suit…; 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the ' 840 patent…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification | External link to document |
2019-10-11 | 315 | Stipulation of Dismissal | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the ’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No. 210500… Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020. 2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A. No. 19-211 are dismissed without | External link to document |
2019-10-24 | 317 | Stipulation | 4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted; WHEREAS, MSN’…(A)(vii)(IV) that, in its opinion, the Asserted Patent is invalid, unenforceable, or would not be infringed…Products prior to the expiration of the Asserted Patent in accordance with the labeling proposed in MSN | External link to document |
2019-10-25 | 319 | Stipulation | 4, 6, 8-13, 15, and 16 of U.S. Patent No. 8,399,514 (“the ’514 patent”) (collectively, the “Asserted …Asserted Claims” of the “Asserted Patent”) by submitting, or causing to be submitted, Abbreviated New Drug Application… WHEREAS claims 5, 7, 14, and 17-20 of the ’514 patent have not been asserted; WHEREAS, Biogen…by Sandoz of the Asserted Claims of the Asserted Patent based Sandoz’s filing of ANDA No. 210414; …Prinston of the Asserted Claims of the Asserted Patent based on Prinston’s filing of ANDA No. 210512; | External link to document |
2019-11-01 | 321 | Stipulation | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 (“…(“the ’001 patent”) 7,803,840 (“the ’840 patent), 8,759,393 (“the ’393 patent”), and 8,399,514 (“the …the ’514 patent”) by submission of Sawai’s Abbreviated New Drug Application (“ANDA”) No. 210285: Biogen… of claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent {01502985;v1 } Case 1:17-cv-00823-MN Document…that claims 1-4, 6, 8-13, 15, and 16 of the ’514 patent are invalid for failure to comply with one or | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |